Applications of dipeptidyl peptidase IV inhibitors in diabetes mellitus

International Journal of Biochemistry and Cell Biology

Volumn 38, Issue 5-6, 2006, Pages 860-872

  McIntosh, Christopher H S ^a   Demuth, Hans Ulrich ^b   Kim, Su Jin ^a,b,c   Pospisilik, J Andrew ^c   Pederson, Raymond A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b PROBIODRUG AG   (Germany)

^c INSTITUTE OF MOLECULAR BIOTECHNOLOGY   (Austria)

Author keywords

Diabetes mellitus; Dipeptidyl peptidase IV; Glucagon like peptide 1; Glucose dependent insulinotropic polypeptide; Incretins

Indexed keywords

6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; AMINOMETHYLPYRIDINE; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; INCRETIN; ISOLEUCINE THIAZOLIDIDE; MK 432; PSN 9301; PYRIDINE DERIVATIVE; PYRROLIDINE DERIVATIVE; SAXAGLIPTIN; THIAZOLIDINE DERIVATIVE; UNCLASSIFIED DRUG; VILDAGLIPTIN; XANTHINE;

B LYMPHOCYTE; CELL DIFFERENTIATION; CELL SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; GLUCAGON RELEASE; GLUCOSE TOLERANCE; HUMAN; IN VIVO STUDY; INSULIN RELEASE; MITOGENESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN DEGRADATION; PRURITUS; REVIEW; STOMACH EMPTYING;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD26; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDES; GLUCOSE; GLUCOSE TOLERANCE TEST; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PROTEASE INHIBITORS;

ANIMALIA;

EID: 33644834521     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2005.12.013     Document Type: Review

References (115)

1. C.A. Abbott, D.M. Yu, E. Woollatt, G.R. Sutherland, and G.W. McCaughan Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8 European Journal of Biochemistry 267 20 2000 6140 6150
2. K. Aertgeerts, S. Ye, M.G. Tennant, M.L. Kraus, J. Rogers, and B.C. Sang Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation Protein Science 13 2 2004 412 421
3. B. Ahrén, J.J. Holst, H. Martensson, and B. Balkan Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice European Journal of Pharmacology 404 1-2 2000 239 245
4. B. Ahrén, and T.E. Hughes Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin releasing peptide in mice Endocrinology 146 4 2005 2055 2059
5. B. Ahrén, M. Landin-Olsson, P.A. Jansson, M. Svensson, D. Holmes, and A. Schweizer Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes Journal of Clinical Endocrinology & Metabolism 89 5 2004 2078 2084
6. B. Ahrén, D. Mills, R. Gomis, A. Schweizer, and E. Standl Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes Diabetes Care 27 12 2004 2874 2880
7. B. Ahrén, E. Simonsson, H. Larsson, M. Landin-Olsson, H. Torgeirsson, and P.A. Jansson Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes Diabetes Care 25 5 2002 869 875
8. K. Augustyns, G. Bal, G. Thonus, A. Belyaev, X.M. Zhang, and W. Bollaert The unique properties of dipeptidyl-peptidase IV (DPP IV/CD26) and the therapeutic potential of DPP IV inhibitors Current Medicinal Chemistry 6 4 1999 311 327
9. U. Aytac, and N.H. Dang CD26/dipeptidyl peptidase IV: A regulator of immune function and a potential molecular target for therapy Current Drug Targets Immune Endocrine & Metabolic Disorders 4 1 2004 11 18
10. B. Balkan, L. Kwasnik, R. Miserendino, J.J. Holst, and X. Li Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats Diabetologia 42 11 1999 1324 1331
11. J. Blanco, C. Nguyen, C. Callebaut, E. Jacotot, B. Krust, and J.P. Mazaleyrat Dipeptidyl-peptidase IV-beta - further characterization and comparison to dipeptidyl-peptidase IV activity of CD26 European Journal of Biochemistry 256 2 1998 369 378
12. W.T. Chen, T. Kelly, and G. Ghersi DPPIV, seprase, and related serine peptidases in multiple cellular functions Current Topics in Developmental Biology 54 2003 207 232
13. H.C. Cheng, M. Abdel-Ghany, R.C. Elble, and B.U. Pauli Lung endothelial dipeptidyl peptidase IV promotes adhesion and metastasis of rat breast cancer cells via tumor cell surface-associated fibronectin Journal of Biological Chemistry 273 37 1998 24207 24215
14. C.H. Chien, L.H. Huang, C.Y. Chou, Y.S. Chen, Y.S. Han, and G.G. Chang One site mutation disrupts dimer formation in human DPP-IV proteins Journal of Biological Chemistry 279 50 2004 52338 52345
15. P.J. Collins, G. McMahon, P. O'Brien, and B. O'Connor Purification, identification and characterisation of seprase from bovine serum International Journal of Biochemistry & Cell Biology 36 11 2004 2320 2333
16. W. Creutzfeldt The entero-insular axis in type 2 diabetes -incretins as therpeutic agents Experimental and Clinical Endocrinology & Diabetes 109 Suppl. 2 2001 S288 S300
17. W. Creutzfeldt, and R. Ebert New developments in the incretin concept Diabetologia 28 8 1985 565 573
18. W. Creutzfeldt, and M.A. Nauck Gut hormones and diabetes mellitus Diabetes-Metabolism Reviews 8 2 1992 565 573
19. W.O. Creutzfeldt, N. Kleine, B. Willms, C. Ørskov, J.J. Holst, and M.A. Nauck Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients Diabetes Care 19 6 1996 580 588
20. I. De Meester, S. Korom, J. Van Damme, and S. Scharpe CD26, let it cut or cut it down Immunology Today 20 8 1999 367 375
21. I. De Meester, A.M. Lambeir, P. Proost, and S. Scharpe Dipeptidyl peptidase IV substrates. An update on in vitro peptide hydrolysis by human DPPIV Advances in Experimental Medicine & Biology 524 2003 3 17
22. I. De Meester, G. Vanhoof, D. Hendriks, H.U. Demuth, A. Yaron, and S. Scharpe Characterization of dipeptidyl peptidase IV (CD26) from human lymphocytes Clinica Chimica Acta 210 1-2 1992 23 34
23. C.F. Deacon, P. Danielsen, L. Klarskov, M. Olesen, and J.J. Holst Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs Diabetes 50 7 2001 1588 1597
24. C.F. Deacon, A.H. Johnsen, and J.J. Holst Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo Journal of Clinical Endocrinology & Metabolism 80 3 1995 952 957
25. C.F. Deacon, M.A. Nauck, J. Meier, K. Hucking, and J.J. Holst Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide Journal of Clinical Endocrinology & Metabolism 85 10 2000 3575 3581
26. C.F. Deacon, S. Wamberg, P. Bie, T.E. Hughes, and J.J. Holst Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs Journal of Endocrinology 172 2 2002 355 362
27. D.J. Drucker Glucagon-like peptides: Regulators of cell proliferation, differentiation and apoptosis Molecular Endocrinology 17 2 2003 161 171
28. D.J. Drucker Enhancing incretin action for the treatment of type 2 diabetes Diabetes Care 26 10 2003 2929 2940
29. D.J. Drucker Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes Expert Opinion on Investigational Drugs 12 1 2003 87 100
30. J.S. Duke-Cohan, J.H. Kim, and A. Azouz Attractin: Cautionary tales for therapeutic intervention in molecules with pleiotropic functionality Journal of Environmental Pathology, Toxicology & Oncology 23 1 2004 1 11
31. J.S. Duke-Cohan, C. Morimoto, J.A. Rocker, and S.F. Schlossman Serum high molecular weight dipeptidyl peptidase IV (CD26) is similar to a novel antigen DPPT-L released from activated T cells Journal of Immunology 156 5 1996 1714 1721
32. J.S. Duke-Cohan, W. Tang, and S.F. Schlossman Attractin: A cub-family protease involved in T cell-monocyte/macrophage interactions Advances in Experimental Medicine & Biology 477 2000 173 185
33. J. Dupre Glycaemic effects of incretins in type 1 diabetes mellitus. A concise review, with emphasis on studies in humans Regulatory Peptides 128 2 2005 149 157
34. J. Dupre, M.T. Behme, I.M. Hramiak, and T.J. McDonald Subcutaneous glucagon-like peptide I combined with insulin normalizes postcibal glycemic excursions in IDDM Diabetes Care 20 3 1997 381 384
35. J. Dupre, M.T. Behme, I.M. Hramiak, P. Mcfarlane, M.P. Williamson, and P. Zabel Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM Diabetes 44 6 1995 626 630
36. C. Durinx, A.M. Lambeir, E. Bosmans, J.B. Falmagne, R. Berghmans, and A. Haemers Molecular characterization of dipeptidyl peptidase activity in serum - soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides European Journal of Biochemistry 267 17 2000 5608 5613
37. + cells in the peripheral blood and thyroid tissue of patients with Graves' disease Journal of Immunology 142 12 1989 4233 4240
38. J.A. Ehses, V.R. Casilla, T. Doty, J.A. Pospisilik, K.D. Winter, and H.U. Demuth Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase Endocrinology 144 10 2003 4433 4445
39. M. Engel, T. Hoffmann, L. Wagner, M. Wermann, U. Heiser, and R. Kiefersauer The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism Proceedings of the National Academy of Sciences of the United States of America 100 9 2003 5063 5068
40. D.M. Evans Dipeptidyl peptidase IV inhibitors IDrugs 5 6 2002 577 585
41. D. Friedrich, K. Kühn-Wache, T. Hoffmann, and H.-U. Demuth Isolation and characterization of attractin-2 Advances in Experimental Medicine & Biology 524 2003 109 113
42. K. Fujita, M. Hirano, J. Ochiai, M. Funabashi, I. Nagatsu, and T. Nagatsu Serum glycylproline p-nitroanilidase activity in rheumatoid arthritis and systemic lupus erythematosus Clinica Chimica Acta 88 1 1978 15 20
43. +exchanger isoform NHE3 and dipeptidyl peptidase IV in the renal proximal tubule Journal of Biological Chemistry 276 49 2001 46671 46677
44. + exchanger isoform NHE3 in proximal tubule cells American Journal of Physiology Cell Physiology 287 5 2004
45. M.D. Gorrell, V. Gysbers, and G.W. McCaughan CD26: A multifunctional integral membrane and secreted protein of activated lymphocytes Scandinavian Journal of Immunology 54 3 2001 249 264
46. M. Gutniak, C. Ørskov, J.J. Holst, B. Ahrén, and S. Efendic Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus New England Journal of Medicine 326 20 1992 1316 1322
47. D.A. Hafler, D.A. Fox, M.E. Manning, S.F. Schlossman, E.L. Reinherz, and H.L. Weiner In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis New England Journal of Medicine 312 22 1985 1405 1411
48. C. Hanski, T. Huhle, R. Gossrau, and W. Reutter Direct evidence for the binding of rat liver DPP IV to collagen in vitro Experimental Cell Research 178 1 1988 64 72
49. T. Hansotia, L.L. Baggio, D. Delmeire, S.A. Hinke, Y. Yamada, and K. Tsukiyama Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors Diabetes 53 5 2004 1326 1335
50. T. Hashikawa, S.W. Hooker, J.G. Maj, C.J. Knott-Craig, M. Takedachi, and S. Murakami Regulation of adenosine receptor engagement by ecto-adenosine deaminase FASEB Journal 18 1 2004 131 133
51. S.A. Hinke, S. Manhart, K. Kuhn-Wache, C. Nian, H.U. Demuth, and R.A. Pederson [Ser2]- and [SerP2] incretin analogs: Comparison of dipeptidyl peptidase IV resistance and biological activities in vitro and in vivo Journal of Biological Chemistry 279 6 2004 3998 4006
52. S.A. Hinke, J.A. Pospisilik, H.U. Demuth, S. Mannhart, K. Kühn-Wache, and T. Hoffmann Dipeptidyl peptidase IV (DPIV/CD26) degradation of glucagon. Characterization of glucagon degradation products and DPIV-resistant analogs Journal of Biological Chemistry 275 6 2000 3827 3834
53. M. Hino, T. Nagatsu, S. Kakumu, S. Okuyama, Y. Yoshii, and I. Nagatsu Glycylprolyl beta-naphthylamidase activity in human serum Clinica Chimica Acta 62 1 1975 5 11
54. T. Hoffmann, K. Glund, C.H.S. McIntosh, R.A. Pederson, M. Hanefeld, and B. Rosenkranz DPPIV-inhibition as treatment of type II diabetes 2001
55. T. Hoffmann, B. Wolf, F. Rosche, S. Fischer, M. Hanefeld, and R.A. Pederson Kinetics of active and inactive plasma GIP in type 2 diabetic patients during treatment with the DP IV-inhibitor P32/98: Direct determination by immunoprecipitation LC-MS Diabetes 51 Suppl. 2 2002 A340
56. J.J. Holst, and C.F. Deacon Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes Diabetes 47 11 1998 1663 1670
57. V.K. Hopsu-Havu, and G.G. Glenner A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide Histochemie 7 3 1966 197 201
58. T. Ishii, K. Ohnuma, A. Murakami, N. Takasawa, S. Kobayashi, and N.H. Dang CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO Proceedings of the National Academy of Sciences of the United States of America 98 21 2001 12138 12143
59. S. Iwaki-Egawa, Y. Watanabe, Y. Kikuya, and Y. Fujimoto Dipeptidyl peptidase IV from human serum: Purification, characterization, and N-terminal amino acid sequence Journal of Biochemistry 124 2 1998 428 433
60. E. Jacotot, C. Callebaut, J. Blanco, B. Krust, K. Neubert, and A. Barth Dipeptidyl-peptidase IV-beta, a novel form of cell-surface-expressed protein with dipeptidyl-peptidase IV activity European Journal of Biochemistry 239 2 1996 248 258
61. T.J. Kieffer, C.H. McIntosh, and R.A. Pederson Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV Endocrinology 136 8 1995 3585 3596
62. D. Kim, L. Wang, M. Beconi, G.J. Eiermann, M.H. Fisher, and H. He (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H) -yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes Journal of Medicinal Chemistry 48 1 2005 141 151
63. K. Kühn-Wache, T. Hoffmann, S. Manhart, W. Brandt, and H.U. Demuth The specificity of DP IV for natural substrates is peptide structure determined Advances in Experimental Medicine & Biology 524 2003 57 63
64. A.M. Lambeir, C. Durinx, S. Scharpe, and I. De Meester Dipeptidyl-peptidase IV from bench to bedside: An update on structural properties, functions, and clinical aspects of the enzyme DPP IV Critical Reviews in Clinical Laboratory Sciences 40 3 2003 209 294
65. G. Lankas, B. Leiting, R.S. Roy, G. Eiermann, T. Biftu, and D. Kim Inhibition of DPP8/9 results in toxicity in preclinical species: Potential importance of selective dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes Diabetes 53 Suppl. 2 2004 A2
66. P.J. Larsen, and J.J. Holst Glucagon-related peptide-1 (GLP-1): Hormone and neurotransmitter Regulatory Peptides 128 2 2005 97 107
67. J.M. Lenhard, and W.K. Gottschalk Preclinical developments in type 2 diabetes Advance Drug Delivery Reviews 54 2002 1199 1212
68. Z. Lojda Studies on dipeptidyl(amino)peptidase IV (glycyl-proline napthylamidase). II. Blood vessels Histochemistry 59 3 1979 153 166
69. S.H. Low, S.H. Wong, B.L. Tang, V.N. Subramaniam, and W.J. Hong Apical cell surface expression of rat dipeptidyl peptidase IV in transfected Madin-Darby canine kidney cells Journal of Biological Chemistry 266 20 1991 13391 13396
70. K. Ludwig, S. Yan, H. Fan, W. Reutter, and C. Bottcher The 3D structure of rat DPPIV/CD26 as obtained by cryo-TEM and single particle analysis Biochemical & Biophysical Research Communications 304 1 2003 73 77
71. F.C. Lynn, N. Pamir, E.H. Ng, C.H. McIntosh, T.J. Kieffer, and R.A. Pederson Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats Diabetes 50 5 2001 1004 1011
72. M. Maes, S. Scharpe, I. De Meester, P. Goossens, A. Wauters, and H. Neels Components of biological variation in prolyl endopeptidase and dipeptidyl-peptidase IV activity in plasma of healthy subjects Clinical Chemistry 40 9 1994 1686 1691
73. D. Marguet, L. Baggio, T. Kobayashi, A.M. Bernard, M. Pierres, and P.F. Nielsen Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26 Proceedings of the National Academy of Sciences of the United States of America 97 12 2000 6874 6879
74. G.W. McCaughan, M.D. Gorrell, G.A. Bishop, C.A. Abbott, N.A. Shackel, and P.H. McGuinness Molecular pathogenesis of liver disease: An approach to hepatic inflammation, cirrhosis and liver transplant tolerance Immunological Reviews 174 2000 172 191
75. C.H.S. McIntosh, H.-U. Demuth, J.A. Pospisilik, and R.A. Pederson Dipeptidyl peptidase IV (DP IV) Inhibitors: How do they work as new antidiabetic agents? Regulatory Peptides 128 2 2005 159 165
76. J.J. Meier, M.A. Nauck, W.E. Schmidt, and B. Gallwitz Gastric inhibitory polypeptide: The neglected incretin revisited Regulatory Peptides 107 1-3 2002 1 13
77. R. Mentlein Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides Regulatory Peptides 85 1 1999 9 24
78. R. Mentlein, B. Gallwitz, and W.E. Schmidt Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum European Journal of Biochemistry 214 3 1993 829 835
79. C. Morimoto, and S.F. Schlossman The structure and function of CD26 in the T-cell immune response Immunological Reviews 161 1998 55 70
80. T. Nagakura, N. Yasuda, K. Yamazaki, H. Ikuta, and I. Tanaka Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition Metabolism: Clinical & Experimental 52 1 2003 81 86
81. T. Nagakura, N. Yasuda, K. Yamazaki, H. Ikuta, S. Yoshikawa, and O. Asano Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats Biochemical & Biophysical Research Communications 284 2 2001 501 506
82. M.A. Nauck, and J.J. Meier Glucagon-like peptide 1 and its derivatives in the treatment of diabetes Regulatory Peptides 128 2 2005 135 148
83. C. Oefner, A. D'Arcy, A. Mac Sweeney, S. Pierau, R. Gardiner, and G.E. Dale High-resolution structure of human apo dipeptidyl peptidase IV/CD26 and its complex with 1-[([2-[(5-iodopyridin-2-yl)amino]-ethyl]amino)-acetyl]-2-cyano- (S)-pyrrolidine Acta Crystallographica Section D: Biological Crystallography 59 Pt. 7 2003 1206 1212
84. C. Olsen, and N. Wagtmann Identification and characterization of human DPP9, a novel homologue of dipeptidyl peptidase IV Gene 299 1-2 2002 185 193
85. R.P. Pauly, H.-U. Demuth, F. Rosche, J. Schmidt, H.A. White, and C.H.S. McIntosh Inhibition of dipeptidyl peptidase IV (DP IV) in rat results in improved glucose tolerance Regulatory Peptides 64 1-3 1996 148
86. R.P. Pauly, H.U. Demuth, F. Rosche, J. Schmidt, H.A. White, and F. Lynn Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide Metabolism: Clinical & Experimental 48 3 1999 385 389
87. R.P. Pauly, F. Rosche, M. Wermann, C.H. McIntosh, R.A. Pederson, and H.U. Demuth Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry. A novel kinetic approach Journal of Biological Chemistry 271 38 1996 23222 23229
88. R.A. Pederson, T.J. Kieffer, R. Pauly, H. Kofod, J. Kwong, and C.H. McIntosh The enteroinsular axis in dipeptidyl peptidase IV-negative rats Metabolism: Clinical & Experimental 45 11 1996 1335 1341
89. R.A. Pederson, H.A. White, D. Schlenzig, R.P. Pauly, C.H. McIntosh, and H.U. Demuth Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide Diabetes 47 8 1998 1253 1258
90. J.A. Pospisilik, J.A. Ehses, T. Doty, C.H.S. McIntosh, H.-U. Demuth, and R. Pederson Dipeptidyl peptidase inhibition in animal models of diabetes Advances in Experimental Medicine and Biology 524 2003 281 291
91. J.A. Pospisilik, S.A. Hinke, R.A. Pederson, T. Hoffmann, F. Rosche, and D. Schlenzig Metabolism of glucagon by dipeptidyl peptidase IV (CD26) Regulatory Peptides 96 3 2001 133 141
92. J.A. Pospisilik, J. Martin, T. Doty, J.A. Ehses, N. Pamir, and F.C. Lynn Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic ratsneogenesis in streptozotocin-induced diabetic rats Diabetes 52 3 2003 741 750
93. J.A. Pospisilik, S.G. Stafford, H.U. Demuth, R. Brownsey, W. Parkhouse, and D.T. Finegood Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats Diabetes 51 4 2002 943 950
94. J.A. Pospisilik, S.G. Stafford, H.U. Demuth, C.H.S. McIntosh, and R.A. Pederson Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: A euglycemic-hyperinsulinemic clamp study Diabetes 51 9 2002 2677 2683
95. G. Püschel, R. Mentlein, and E. Heymann Isolation and characterization of dipeptidyl peptidase IV from human placenta European Journal of Biochemistry 126 2 1982 359 365
96. H.B. Rasmussen, S. Branner, F.C. Wiberg, and N. Wagtmann Crystal structure of dipeptidyl peptidase IV/CD26 in complex with a substrate analog Nature Structural Biology 10 1 2003 19 25
97. M.K. Reimer, J.J. Holst, and B. Ahrén Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice European Journal of Endocrinology 146 5 2002 717 727
98. N. Rolin, H. Nygaard, M. Wilken, A.B. Kanstrup, and R.D. Carr The novel, xanthine-based, DPPIV inhibitor NN7201 and LAF237 improve glucose tolerance, but do not prevent progression of diabetes in diabetic fatty rats Diabetes 53 Suppl. 2 2004 A340
99. H. Shibuya-Saruta, Y. Kasahara, and Y. Hashimoto Human serum dipeptidyl peptidase IV (DPPIV) and its unique properties Journal of Clinical Laboratory Analysis 10 6 1996 435 440
100. A. Steinbrecher, D. Reinhold, L. Quigley, A. Gado, N. Tresser, and L. Izikson Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and up-regulates TGF-beta 1 secretion in vivo Journal of Immunology 166 3 2001 2041 2048
101. B. Sudre, P. Broqua, R.B. White, D. Ashworth, D.M. Evans, and R. Haigh Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male Zucker diabetic fatty rats Diabetes 51 5 2002 1461 1469
102. W. Tang, T.M. Gunn, D.F. McLaughlin, G.S. Barsh, S.F. Schlossman, and J.S. Duke-Cohan Secreted and membrane attractin result from alternative splicing of the human ATRN gene Proceedings of the National Academy of Sciences of the United States of America 97 11 2000 6025 6030
103. R. Thoma, B. Loffler, M. Stihle, W. Huber, A. Ruf, and M. Hennig Structural basis of proline-specific exopeptidase activity as observed in human dipeptidyl peptidase-IV Structure 11 8 2003 947 959
104. A. Trümper, K. Trümper, H. Trusheim, R. Arnold, B. Göke, and D. Hörsch Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling Molecular Endocrinology 15 9 2001 1559 1570
105. R. Underwood, M. Chiravuri, H. Lee, T. Schmitz, A.K. Kabcenell, and K. Yardley Sequence, purification, and cloning of an intracellular serine protease, quiescent cell proline dipeptidase Journal of Biological Chemistry 274 48 1999 34053 34058
106. R.H. Unger, and A.M. Eisentraut Entero-insular axis Arch. Intern. Med. 123 3 1969 261 266
107. G. Vanhoof, I. De Meester, M. van Sande, S. Scharpe, and A. Yaron Distribution of proline-specific aminopeptidases in human tissues and body fluids European Journal of Clinical Chemistry & Clinical Biochemistry 30 6 1992 333 338
108. J.I. Venäläinen, R.O. Juvonen, and P.T. Männistö Evolutionary relationships of the prolyl oligopeptidase family enzymes European Journal of Biochemistry 271 13 2004 2705 2715
109. E.B. Villhauer, J.A. Brinkman, G.B. Naderi, B.F. Burkey, B.E. Dunning, and K. Prasad 1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: A potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties Journal of Medicinal Chemistry 46 13 2003 2774 2789
110. E.B. Villhauer, J.A. Brinkman, G.B. Naderi, B.E. Dunning, B.L. Mangold, and M.D. Mone 1-[2-[(5-Cyanopyridin-2-yl)amino]ethylamino]acetyl-2-(S)- pyrrolidinecarbonitrile: A potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties Journal of Medicinal Chemistry 45 12 2002 2362 2365
111. T. Vilsbøll, and J.J. Holst Incretins, insulin secretion and type 2 diabetes mellitus Diabetologia 47 3 2004 357 366
112. A.E. Weber Dipeptidyl peptidase IV inhibitors for the treatment of diabetes Journal of Medicinal Chemistry 47 17 2004 4135 4141
113. P.E. Wiedeman, and J.M. Trevillyan Dipeptidyl peptidase IV inhibitors for type 2 diabetes and metabolic syndrome Drug Discovery Today Therapeutic Strategies 2 2 2005 143 149
114. N. Yasuda, T. Inoue, T. Nagakura, K. Yamazaki, K. Kira, and T. Saeki Enhanced secretion of glucagon-like peptide 1 by biguanide compounds Biochemical & Biophysical Research Communications 298 5 2002 779 784
115. N. Yasuda, T. Inoue, T. Nagakura, K. Yamazaki, K. Kira, and T. Saeki Metformin causes reduction of food intake and body weight gain and improvement of glucose intolerance in combination with dipeptidyl peptidase IV inhibitor in Zucker fa/fa rats Journal of Pharmacology and Experimental Therapeutics 310 2 2004 614 619